Celecoxib

Licensed by Pfizer 製品コードS1261 別名:SC 58635

Celecoxib化学構造

分子量(MW):381.37

セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。

サイズ 価格(税別)  
JPY 16102.00
JPY 44820.00

カスタマーフィードバック(3)

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

製品安全説明書

COX阻害剤の選択性比較

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット
COX-2 [1]
(Sf9 cells)
40 nM
体外試験

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NV;5U3FZTnWwY4Tpc44hSXO|YYm= MoXUNE4yNTNyIN88US=> Moj2OFghcA>? M1fXeIlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt MXiyOlUyOzF5Mh?=
H460 MnvESpVv[3Srb36gRZN{[Xl? NYHTT483OC5zLUOwJO69VQ>? M2fNelQ5KGh? MnPkbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NFPpd5kzPjVzM{G3Ni=>
HKESC-2 NYX4T5hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fMVFIxyqEQvF2= NEDE[JE1QMLiaNMg NH\TVJl{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? Moj2NlY1PzR4OUO=
CaES-17 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK0VnYzOMLizszN MmLyOFjDqGkEoB?= NF\PUWh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? NXjGV4tyOjZ2N{S2PVM>
HKESC-2 MlHoRZBweHSxc3nzJGF{e2G7 M2WycVIxyqEQvF2= NXPscWcyPDkEoHlCpC=> M3LETJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MV:yOlQ4PDZ7Mx?=
CaES-17 MWLBdI9xfG:|aYOgRZN{[Xl? NVS4e2ZNOjEEoN88US=> NEDZOms1QMLiaNMg M37TOJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> M1S1UFI3PDd2Nkmz
A549 M3m4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfOXVY2NTF4MDFOwG0> M{jJZlQ5yqCqwrC= MXzEUXNQ MYXJR|UxRTF4Mz60JO69VQ>? MnPkNlY1PjR4NEO=
HCC827 NV\qPYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnJR|dCPS1zNkCg{txO Mm\qOFjDqGkEoB?= NFnXPGJFVVOR MV7JR|UxRTZ7LkKg{txO M2HMVFI3PDZ2NkSz
A549 NXznZ2dPSXCxcITvd4l{KEG|c3H5 NFXCZ2c5OCEEtV2= MUW0POKhcMLi M3ruS2ROW09? NGnnWYxqdmS3Y3XzJIFxd3C2b4Ppdy=> NYrmOYlNOjZ2NkS2OFM>
HCC827 MlvLRZBweHSxc3nzJGF{e2G7 MVu4NEDDvU1? NVfEO3BzPDkEoHlCpC=> MmXVSG1UVw>? NHuz[mJqdmS3Y3XzJIFxd3C2b4Ppdy=> MlS2NlY1PjR4NEO=
SGC-7901/DDP MXrGeY5kfGmxbjDBd5NigQ>? MX6xNOKhyrWP MYiyOEBp MWPpcohq[mm2czDjfYNtd2:6eXflcoF{\S1{IHHu[EBRNWeueXPvdJJwfGWrbjDlfJBz\XO|aX;u NUH1T2FnOjZ2MEe2OVM>
SGC-7901  M2fOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fqelI1yqCqwrC= NFjIUY1KSzVyPUGxOU4xQCEQvF2= MVuyOlQxPzZ3Mx?=
SGC-7901/DDP M1XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS2NlTDqGkEoB?= M4nRRmlEPTB;M{WuOFUh|ryP MXGyOlQxPzZ3Mx?=
SGC-7901/DDP NFPHb5lCeG:ydH;zbZMhSXO|YYm= NXr6bIYyOTEEoNM1US=> M4\GelI1KGh? NUPWN4VpcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDD3bZRpKGOrc4DsZZRqdg>? Ml:zNlY1ODd4NUO=
SGC-7901/DDP NWDPXHB5TnWwY4Tpc44hSXO|YYm= NH7CWokyOMLiwsXN NGLmbG4zPCCq MVnpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>? M4Ow[VI3PDB5NkWz
SGC-7901/DDP NHvnZ4xHfW6ldHnvckBCe3OjeR?= NH7qS|EyOMLiwsXN NXj1WmZ1OjRiaB?= MoPQZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu M4\zWFI3PDB5NkWz
H357 NILWUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHoSotPPy53L{GwJO69VQ>? NYfncVcyPDhiaB?= M{XWTGROW09? NUjUbGd1cW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? MUWyOlAxQTh5NB?=
TAF NGS1U2ZHfW6ldHnvckBCe3OjeR?= NIezV4MyOMLiwsXN MVu3JIQ> NGnRTGli\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= M120flI2QTh5MUK3
TAF M2HLVGZ2dmO2aX;uJGF{e2G7 NGjkZXUyOMLiwsXN NIPjNGk{OC1zMkCgcYlv NU\CZ4EzeG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o NEe3WXUzPTl6N{GyOy=>
TAF NV76WYpZTnWwY4Tpc44hSXO|YYm= M{DIcFExyqEEtV2= NXT4[4tRPDhiaB?= NFPqbXpqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NF3CUIkzPTl6N{GyOy=>
PANC-1 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TaclIxNzZyL{GwNEDPxE1? MU[yOE81QC95MjDo NH2zdo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{XZWVI2QTd|ME[y
PANC-1 NInLdWlHfW6ldHnvckBCe3OjeR?= MYiyNE83OC9zMECg{txO MmDINlQhcA>? NHi3fnRifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MVKyOVk4OzB4Mh?=
HeLa  MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37z[VIxyqEQvF5CpC=> NW[ybHJXOjUEoHi= M1HqOoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NFfVeGIzPTd5MESyNy=>
SACC-83 M1LiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPjfG8zOMLizszNxsA> MXSyOOKhcA>? NFLudlBmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= M1fWfFI2PzdyNEKz
HeLa  NIH2O3hCeG:ydH;zbZMhSXO|YYm= MYqyNOKh|ryPwrC= MmX4NlTDqGh? MlLi[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> M1mz[VI2PzdyNEKz
SACC-83 NXTX[21jSXCxcITvd4l{KEG|c3H5 NFHOeXAzOMLizszNxsA> NInQV5gzPMLiaB?= NW\KdZFz\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? M3Gxb|I2PzdyNEKz
HeLa  M4j0UWZ2dmO2aX;uJGF{e2G7 NWDTTWpbOjBxNECvPFAh|ryP NH25doEzPMLiaB?= MmTLeZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> NUjK[Yc{OjV5N{C0NlM>
SACC-83 MknESpVv[3Srb36gRZN{[Xl? MnfQNlAwPDBxOECg{txO NFq3UXczPMLiaB?= M362cpVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NXjhbYpLOjV5N{C0NlM>
HLCZ01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonENQKBmzZywrFCuW0> NXzZelBJPDhiaB?= NGLpVW1FVVOR M{XBfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYKzSlE2OjV5MkS4PVk>
HLCZ01 MkPXSpVv[3Srb36gRZN{[Xl? NIHZcVM1OMLizszN NViwWmlpOjRiaB?= MlfsSG1UVw>? M{nqZ4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MlXGNlU4OjR6OUm=
HLCZ01 MYjBdI9xfG:|aYOgRZN{[Xl? MVm0NOKh|ryP NX3DVG9mOjRiaB?= MWTEUXNQ M4nkeYVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? NXPaTXhTOjV5MkS4PVk>
HLCZ01 M3T3[GZ2dmO2aX;uJGF{e2G7 M4rleVQxyqEQvF2= NU\tb4syOjRiaB?= M125OWROW09? MoS2bY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x M{nkbVI2PzJ2OEm5
MGC803 M37Qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfRU2gxNTZyIN88US=> NWXwN29oPzJiaB?= MlTmTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= MUiyOVcxOTN5OB?=
SGC7901 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv3TYs2OC14MDFOwG0> NHvtZ4U4OiCq NFHFZ4ZKSzVyPUSzMlU{6oDLwsJihKk2NjF{IN88US=> Mnm1NlU4ODF|N{i=
MGC803 M13zbWZ2dmO2aX;uJGF{e2G7 M4L1NlQxyqEQvF2= MkLaPE8yPi9{NDDo M1\wbpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MVuyOVcxOTN5OB?=
SGC7901 MUnGeY5kfGmxbjDBd5NigQ>? MmK0OFDDqM7:TR?= MX64M|E3NzJ2IHi= Mm\veZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MmDyNlU4ODF|N{i=
MCF-7  M{fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxM|ExKM7:TR?= NISyOZU4OiCq MkjQSG1UVw>? MWPlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? NITYc2ozPTZ4N{WxNC=>
MDA-MB-231  NUTYelJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj1OGoyNzFyIN88US=> NU\iWpA{PzJiaB?= MYjEUXNQ MYHlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? M4PGVFI2PjZ5NUGw
MDA-MB-231 M121OGZ2dmO2aX;uJGF{e2G7 NELPUnoxNTRyINM1US=> MXq0MVI1KGh? NUS0dmg3cW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGHvZZAzPTV6N{OyPS=>
MCF-7 NXHTemFxTnWwY4Tpc44hSXO|YYm= M2jmTVAuPDBiwsXN NVPONYIzPC1{NDDo NH3YVVlmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MWGyOVU5PzN{OR?=
MCF7-MX  NVm4c5pGTnWwY4Tpc44hSXO|YYm= M2HaSlAuPDBiwsXN NW\EXFZSPC1{NDDo M{\YVIVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NFLpV4gzPTV6N{OyPS=>
MDA-MB-231 NIrUUXdHfW6ldHnvckBCe3OjeR?= MUCwMVQxKML3TR?= MY[0MVI1KGh? M3\VbJN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= NVvjTJBOOjV3OEezNlk>
A2780 M3nL[mZ2dmO2aX;uJGF{e2G7 M1:zUlUwOTBxMUWg{txO NWHuN4U6PDhiaB?= NFqw[Xpl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYHJTVV5OjV2MkS4PVg>
SKOV3  MVnGeY5kfGmxbjDBd5NigQ>? NYjnRY5mPS9zMD:xOUDPxE1? NWfHdWhsPDhiaB?= Ml:2[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmLPNlU1OjR6OUi=
A2780 Mn:5SpVv[3Srb36gRZN{[Xl? MYi1M|ExNzF3IN88US=> MXm0PEBp MXLlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv Mnq2NlU1OjR6OUi=
SKOV3  NYnLO4tsTnWwY4Tpc44hSXO|YYm= M3nFVVUwOTBxMUWg{txO NEnNVW01QCCq NWLCPIRQ\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= M4HuOVI2PDJ2OEm4
A2780 NGPVZWVHfW6ldHnvckBCe3OjeR?= NIP0RZE2NzFyL{G1JO69VQ>? MWi0PEBp NV7KPVRN\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu Mn3pNlU1OjR6OUi=
SKOV3  MWDGeY5kfGmxbjDBd5NigQ>? NGDqVms2NzFyL{G1JO69VQ>? NXLxVJg{PDhiaB?= M3LMZ4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= NYnmW5BrOjV2MkS4PVg>
A2780 MVLGeY5kfGmxbjDBd5NigQ>? MV[1M|ExNzF3IN88US=> MU[xJIg> M3PScIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3m2[lI2PDJ2OEm4
SKOV3  NHjQOHhHfW6ldHnvckBCe3OjeR?= NV;Nd5U5PS9zMD:xOUDPxE1? M2P1XFEhcA>? MnHlbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4\C[FI2PDJ2OEm4
HCT-15 MmftSpVv[3Srb36gRZN{[Xl? MontNVAuPTBizszN M13YOFYuOzZiaB?= MUjpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M3m4T|I2OjF6MEK4
HT-29  M{HKO2Z2dmO2aX;uJGF{e2G7 NWTw[IdFOTBvNUCg{txO NID3c4c3NTN4IHi= MkTsbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NGTKTWYzPTJzOECyPC=>
HSC3  MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NITaTFEx6oDVNECg{txO M{fUPFQ5KGh? NFXqWXBKSzVyPUK1MlXDuTFwN{iwJO69VQ>? NFjycnkzPTF7OEe4PS=>
HSC3  MUnBdI9xfG:|aYOgRZN{[Xl? M4GwTVI2KM7:TR?= MVe0PEBp MofpbY5lfWOnczDhdI9xfG:|aYO= NYjxfXZZOjVzOUi3PFk>
HSC3  NILaS|BHfW6ldHnvckBCe3OjeR?= NGrlflUzPSEQvF2= MXO0PEBp MoDk[ZhpcWKrdIOgd4lodmmoaXPhcpRtgSC{ZXT1Z4VlKG2rZ4LheIlwdiClb33ibY5m\CC5aYToJGNGXA>? MY[yOVE6QDd6OR?=
HSC3  M1\vWmZ2dmO2aX;uJGF{e2G7 Ml;kNlUh|ryP NXj5TnhbPDhiaB?= MlLYbY5pcWKrdIOgTHNEOyClZXzsJIlvfmG|aX;uJINwdWKrbnXkJJdqfGhiQ1XU NHuzZpgzPTF7OEe4PS=>
HSC3  M3XQTGZ2dmO2aX;uJGF{e2G7 MXyyOUDPxE1? NYHIfGJXPzJiaB?= MnHN[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg M{nBcFI2OTl6N{i5
201T  M3XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjnSXh2PzJiaB?= Ml24SG1UVw>? MUHJR|UxRTR6Lk[gxtVO NXXhXYhiOjVyNUe5OFE>
273T NFvv[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfNO|IhcA>? MV\EUXNQ MU\JR|UxRThyLkWgxtVO NH;RNWszPTB3N{m0NS=>
Hep-2 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGzNE82OC9zMECg{txO MnX5NVIwOjRxM{[vOFghcA>? Mlu3SG1UVw>? Mn7ybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4nk[FI1QTl6NU[0
Hep-2 NH\rVFZCeG:ydH;zbZMhSXO|YYm= NV;4PVI4PTBizszN MnXjNE01QCCq MnO2SG1UVw>? MlTobY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MUeyOFk6QDV4NB?=
Hep-2 NWXSSJBVTnWwY4Tpc44hSXO|YYm= M1zqWlUxKM7:TR?= M3LZdVAuPDhiaB?= M136bWROW09? M2rwOpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 Mn\kNlQ6QTh3NkS=
Hep-2 M4rQUGZ2dmO2aX;uJGF{e2G7 MnPKOVAh|ryP Mn\0NE01QCCq Mm\nSG1UVw>? NX7QdXBL\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? NYDpS2lxOjR7OUi1OlQ>
SGC-7901 NXvUWXJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljtNVAwPTBxMUCwJO69VQ>? NG\ZcIIzPC92OD:3NkBp MYrEUXNQ NXnI[mo1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MluxNlQ6QTJ7NUi=
MKN-45 NWfU[W9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHiNVAwPTBxMUCwJO69VQ>? NXrsXIFTOjRxNEivO|IhcA>? NG\aVnRFVVOR M1;Tb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MYWyOFk6Ojl3OB?=
SGC-7901 NEP1c4JHfW6ldHnvckBCe3OjeR?= MWmxNE82OC9zMECg{txO NI\mVWY1QCCq MVrEUXNQ M4i2b4Rwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGLTTm8zPDl7Mkm1PC=>
MKN-45 MVLGeY5kfGmxbjDBd5NigQ>? NFHaW4EyOC93MD:xNFAh|ryP MVS0PEBp NFr1fHhFVVOR M3[3TYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NI\iV5czPDl7Mkm1PC=>
C666-1 MkewR5l1d3SxeHnjbZR6KEG|c3H5 Mo\mNlAuQDBizszN NX;xSVNkOjRiaB?= NFnaOXRl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MoT1NlQ5PTR6M{i=
CNE-1 MnviR5l1d3SxeHnjbZR6KEG|c3H5 M1i1[|IxNThyIN88US=> NEjmbYszPCCq M2ewPIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MlLlNlQ5PTR6M{i=
CNE-2 NH7QU2xEgXSxdH;4bYNqfHliQYPzZZk> MXqyNE05OCEQvF2= NEfiRWwzPCCq NXnC[JVS\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MV:yOFg2PDh|OB?=
C666-1 M2LzUWN6fG:2b4jpZ4l1gSCDc4PhfS=> MnTWOlAh|ryP MWe3JIQ> M4XNSoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MVGyOFg2PDh|OB?=
CNE-1 NIHZfoxEgXSxdH;4bYNqfHliQYPzZZk> MUS2NEDPxE1? MlLLO{Bl MmnM[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= MoHZNlQ5PTR6M{i=
SNU-1041 M3Hp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm1SHZMOC12MDFOwG0> Ml\UOFghcA>? Mmm5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWKyOFY6OjdyMx?=
SNU-1041 M4DESmZ2dmO2aX;uJGF{e2G7 NEXBcFgzOC9|MDFOwG0> MVi0JIg> MnTsbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> MmLnNlQ3QTJ5MEO=
SNU-1041 NHe0OHVHfW6ldHnvckBCe3OjeR?= MnXaNE01OCEQvF2= NUDENJE1PCCq NGrkWnB2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= MVOyOFY6OjdyMx?=
SGC-7901 NGrWcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO1NE0yOjVizszN M1T5S|I1NzR6L{eyJIg> MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUmyOFY4PjN7NB?=
SGC-7901 MUjBdI9xfG:|aYOgRZN{[Xl? NHjkZYwyODBizszN M4X0bFczKGh? NGXRZnlqdmS3Y3XzJIFxd3C2b4Ppdy=> NUHhZmRYOjR4N{[zPVQ>
SGC-7901 MWXGeY5kfGmxbjDBd5NigQ>? MVO3OU8yODBxMUK1JO69VQ>? MXiyOE81QC95MjDo MnzVbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK= MnzvNlQ3PzZ|OUS=
LMeC  NES1dmRHfW6ldHnvckBCe3OjeR?= MUeyNE82OCEQvF2= MUe0PEBp M1HVXoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw Mn3TNlQ3PTZ5NE[=
CMeC-1 NYXVeZZuS2WubDDWbYFjcWyrdImgRZN{[Xl? M4iy[FIxNzVyIN88US=> NX;meXFKPDhiaB?= NV33W|c3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYCyOFY2Pjd2Nh?=
LMeC M3uxTWNmdGxiVnnhZoltcXS7IFHzd4F6 M4\6eVIxNzVyIN88US=> NWjkZ|BzPDhiaB?= MUDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXGyOFY2Pjd2Nh?=
CMeC-1 MVvGeY5kfGmxbjDBd5NigQ>? M3nxblIxNzVyIN88US=> M1m2[lQ5KGh? NITGU5JqdmS3Y3XzJGcyNVNiYYLy[ZN1 NWLHWo9sOjR4NU[3OFY>
LMeC NYHnXpJOTnWwY4Tpc44hSXO|YYm= Ml\SNlAwPTBizszN MWK0PEBp M{Dleolv\HWlZYOgS|EuWyCjcoLld5Q> MWqyOFY2Pjd2Nh?=
CMeC-1 MnzUSpVv[3Srb36gRZN{[Xl? M4PwXFIxNzVyIN88US=> MXm0PEBp NE\4cZVl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFHiO4YzPDZ3Nke0Oi=>
LMeC MWrGeY5kfGmxbjDBd5NigQ>? M{LCbVIxNzVyIN88US=> M2\GelQ5KGh? M{LYV4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEWxSWQzPDZ3Nke0Oi=>
CMeC-1 NXvwVlNGTnWwY4Tpc44hSXO|YYm= NWPsRnZ4OjBxNUCg{txO NWHPUmR{PDhiaB?= Mkj3bY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MWiyOFY2Pjd2Nh?=
LMeC Mk[1SpVv[3Srb36gRZN{[Xl? M2jFZ|IxNzVyIN88US=> MXu0PEBp M3j3VYlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MYiyOFY2Pjd2Nh?=
OVCAR-3 MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF3zXYQyOCEEtV2= MlHTNUBp M1ThXIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MV:yOFUzODJ{Nx?=
OVCAR-3 NXXD[JBqSXCxcITvd4l{KEG|c3H5 MY[xNEDDvU1? NXjCS2kzOSCq NYXKPY5DeHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NVL3[nh2OjR3MkCyNlc>
OVCAR-3 M1[5bWZ2dmO2aX;uJGF{e2G7 MW[xNEDDvU1? NX;wV3hIOSCq Mk\3[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S17wrC= MUOyOFUzODJ{Nx?=
OVCAR-3 MVPGeY5kfGmxbjDBd5NigQ>? NF3wOWQyOCEEtV2= NUXQV2E5OSCq M1\VboRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> NFrQUIkzPDV{MEKyOy=>
OVCAR-3 NGrUV5NHfW6ldHnvckBCe3OjeR?= M2PrSFExKML3TR?= M{W5fFEhcA>? MYPpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MnrlNlQ2OjB{Mke=
CF33 NF\2NIxHfW6ldHnvckBCe3OjeR?= NYTRbpAzOTByIN88US=> M1m3U|I1KGh? NX7kfJYxcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= MnHiNlQ2ODN5OEK=
CF33 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTQN3VYOTBvMUCwJO69VQ>? MoTLNE01KGR? NF;jcWpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmXaNlQ2ODN5OEK=
CF33 M{HCeWZ2dmO2aX;uJGF{e2G7 NFLlOlQyOC1zMECg{txO M1q0SFQuOjRiaB?= NUjFUWFn\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 NF\oWWgzPDVyM{e4Ni=>
LNCaP MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HEeVIwPS9zMDFOwG0> NFjKTnQ6PiCq M2GwbYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= M2\rW|I1Ojl4OUe4
LNCaP MWTBdI9xfG:|aYOgRZN{[Xl? M2nKWlIwPS9zMDFOwG0> MUO5OkBp MUPpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= MnrONlQzQTZ7N{i=
PC-3  MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DkN|AuPTBizszN M{D0SlQ56oDLaB?= M2XMO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3;sdlI1OTJ5OEiy
PC-3  MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmPhNE0yODBizszN MlzxO|IhcA>? NETTZYNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NUWze5J2OjRzMke4PFI>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
細胞試験: [2]
+ 展開
  • 細胞株: HNE1 and CNE1-LMP1
  • 濃度: 0-75 μM
  • 反応時間: 48 hours
  • 実験の流れ: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • 製剤: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • 投薬量: ≤200 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管
別名 SC 58635

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • 回答:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX信号経路図

COX Inhibitors with Unique Features

相関COX製品

Tags: Celecoxibを買う | Celecoxib ic50 | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib化学構造 | Celecoxib分子量 | Celecoxib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID